As a new class of drugs, sodium-glucose co-transporter 2 (SGLT2) inhibitors are recommended in a report on hyperglycaemia management released by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).9 SGLT2 inhibitors activate at the proximal nephron to decrease glucose absorption, so they are independent of insulin and therefore can be used in any stage of type 2 diabetes. This evidence concerns the gene SLC5A2 and Hyperglycemia.